ES2534582T3 - Procedimiento para diagnosticar una enfermedad neurodegenerativa - Google Patents
Procedimiento para diagnosticar una enfermedad neurodegenerativa Download PDFInfo
- Publication number
- ES2534582T3 ES2534582T3 ES10182499.3T ES10182499T ES2534582T3 ES 2534582 T3 ES2534582 T3 ES 2534582T3 ES 10182499 T ES10182499 T ES 10182499T ES 2534582 T3 ES2534582 T3 ES 2534582T3
- Authority
- ES
- Spain
- Prior art keywords
- disease
- alzheimer
- expression
- level
- diagnose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
- G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Procedimiento para el diagnóstico de la enfermedad de Alzheimer, que comprende la medición del nivel de expresión de la proteína de la glutatión S-transferasa de tipo silvestre identificada por el número de acceso de SwissProt P78417 en una muestra de plaquetas aisladas de una persona que se sospecha que tiene la enfermedad de Alzheimer, y determinar si el nivel de la expresión está alterado en comparación con un control, en donde un incremento del nivel de expresión de la proteína de la glutatión S-transferasa de tipo silvestre identificada por el número de acceso de SwissProt P78417 cuando se compara con un control sano sin enfermedad indica la presencia de la enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0512401.1A GB0512401D0 (en) | 2005-06-17 | 2005-06-17 | Method |
GB0512401 | 2005-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2534582T3 true ES2534582T3 (es) | 2015-04-24 |
Family
ID=34855743
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10182499.3T Active ES2534582T3 (es) | 2005-06-17 | 2006-06-19 | Procedimiento para diagnosticar una enfermedad neurodegenerativa |
ES10183043.8T Active ES2533086T3 (es) | 2005-06-17 | 2006-06-19 | Método para el diagnóstico de una enfermedad neurodegenerativa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10183043.8T Active ES2533086T3 (es) | 2005-06-17 | 2006-06-19 | Método para el diagnóstico de una enfermedad neurodegenerativa |
Country Status (5)
Country | Link |
---|---|
US (2) | US20080318229A1 (es) |
EP (8) | EP1891445A2 (es) |
ES (2) | ES2534582T3 (es) |
GB (1) | GB0512401D0 (es) |
WO (1) | WO2006134390A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009074331A2 (en) * | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
DE102007062847A1 (de) * | 2007-12-21 | 2009-12-31 | Protagen Ag | Markersequenzen für neurodegenerative Erkrankungen und deren Verwendung |
BRPI0906858B8 (pt) | 2008-01-18 | 2021-07-27 | Harvard College | métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer. |
WO2010084327A2 (en) | 2009-01-26 | 2010-07-29 | Electrophoretics Limited | Methods |
GB0906458D0 (en) | 2009-04-15 | 2009-05-20 | Randox Lab Ltd | Macromolecules for diagnosis and prognosis |
GB0921447D0 (en) * | 2009-12-04 | 2010-01-20 | Randox Lab Ltd | Assay |
US20130316338A1 (en) * | 2010-06-29 | 2013-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | CCR6 As A Biomarker of Alzheimer's Disease |
BR112013001752A2 (pt) | 2010-07-23 | 2016-05-31 | Harvard College | método de detectar doenças ou condições usando células fagocídicas |
EP2596116A4 (en) | 2010-07-23 | 2014-03-19 | Harvard College | METHODS FOR DETECTION OF AUTOIMMUNE OR IMMUNE-RELATED DISEASES / PATHOLOGIES |
US20120053073A1 (en) | 2010-07-23 | 2012-03-01 | President And Fellows Of Harvard College | Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids |
AU2011280936A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
GB201104286D0 (en) * | 2011-03-15 | 2011-04-27 | Randox Lab Ltd | Glutathione S-transferase omega 1 wild type specific antibody |
WO2012175674A1 (en) * | 2011-06-24 | 2012-12-27 | Baden-Württemberg Stiftung Ggmbh | Diagnosis and/or prognosis of a neurodegenerative disease |
GB201122227D0 (en) | 2011-12-23 | 2012-02-01 | Randox Lab Ltd | MAO-B inhibitors derived from the one-carbon cycle |
BR112014031414A2 (pt) | 2012-06-15 | 2017-06-27 | Stylli Harry | métodos de detectar doenças ou condições utilizando células doentes circulantes |
CN104603289A (zh) | 2012-06-15 | 2015-05-06 | 哈里·斯泰利 | 检测疾病或病状的方法 |
GB201212084D0 (en) | 2012-07-06 | 2012-08-22 | Randox Lab Ltd | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment |
GB201217688D0 (en) | 2012-10-03 | 2012-11-14 | Randox Lab Ltd | Method |
GB2511525A (en) * | 2013-03-05 | 2014-09-10 | Randox Teoranta | Methods and Compositions for the Diagnosis of Alzheimer's Disease |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
EP2965086A4 (en) | 2013-03-09 | 2017-02-08 | Harry Stylli | Methods of detecting prostate cancer |
GB201320164D0 (en) * | 2013-11-15 | 2014-01-01 | Randox Lab Ltd | Sample preparation method for analysis of platelet proteins |
WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
CN110891582A (zh) * | 2017-06-16 | 2020-03-17 | 里尔大学中心医院 | 制备混合人血小板裂解液的方法、混合人血小板裂解液及其用于治疗神经系统疾病的用途 |
CN114966048A (zh) * | 2022-05-12 | 2022-08-30 | 东南大学 | 血小板AβPP比值在阿尔茨海默病筛查中的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756479A (en) * | 1994-12-29 | 1998-05-26 | Research Development Foundation | Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
EP0874242B2 (en) | 1997-04-21 | 2009-06-03 | Randox Laboratories Ltd. | Device and apparatus for the simultaneous detection of multiple analytes |
NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
WO2000006730A2 (en) * | 1998-07-31 | 2000-02-10 | Incyte Pharmaceuticals, Inc. | Human cytoskeletal proteins |
AU2001261007A1 (en) * | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030064411A1 (en) * | 2000-12-08 | 2003-04-03 | Herath Herath Mudiyanselage Athula Chandrasiri | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease |
DE10100121A1 (de) * | 2001-01-03 | 2002-08-01 | Henkel Kgaa | Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro |
EP2500440B1 (en) * | 2002-12-20 | 2015-12-16 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
JP2007515155A (ja) * | 2003-10-16 | 2007-06-14 | ノバルティス アクチエンゲゼルシャフト | 異なって発現される冠動脈疾患関連遺伝子 |
TWI281473B (en) * | 2003-12-19 | 2007-05-21 | Ind Tech Res Inst | Biomarkers for liver diseases and method for using same |
AU2005216922A1 (en) * | 2004-02-26 | 2005-09-09 | Icoria, Inc. | Diagnosis of hyperinsulinemia and type II diabetes and protection against same based on genes differentially expressed in muscle cells |
WO2005110460A2 (en) * | 2004-04-29 | 2005-11-24 | Ohio University | Diagnosis and treatment methods related to aging, especially in muscle (14.1) |
EP1797425A2 (en) * | 2004-07-19 | 2007-06-20 | University of Rochester | Biomarkers of neurodegenerative disease |
EP1775590A1 (en) * | 2005-10-11 | 2007-04-18 | Laboratorios S.A.L.V.A.T., S.A. | Non-invasive in vitro method to detect transitional cell carcinoma of the bladder |
-
2005
- 2005-06-17 GB GBGB0512401.1A patent/GB0512401D0/en not_active Ceased
-
2006
- 2006-06-19 EP EP06744252A patent/EP1891445A2/en not_active Withdrawn
- 2006-06-19 US US11/922,229 patent/US20080318229A1/en not_active Abandoned
- 2006-06-19 EP EP10183043.8A patent/EP2293073B1/en active Active
- 2006-06-19 EP EP16150696.9A patent/EP3031823B1/en active Active
- 2006-06-19 EP EP10182499.3A patent/EP2339348B1/en active Active
- 2006-06-19 ES ES10182499.3T patent/ES2534582T3/es active Active
- 2006-06-19 EP EP10183566A patent/EP2293075A3/en not_active Withdrawn
- 2006-06-19 WO PCT/GB2006/002229 patent/WO2006134390A2/en active Application Filing
- 2006-06-19 EP EP10182567.7A patent/EP2287618B1/en active Active
- 2006-06-19 EP EP10183409A patent/EP2293074A3/en not_active Withdrawn
- 2006-06-19 ES ES10183043.8T patent/ES2533086T3/es active Active
- 2006-06-19 EP EP10182533.9A patent/EP2287617B1/en active Active
-
2016
- 2016-02-12 US US15/043,238 patent/US20160161508A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2293075A2 (en) | 2011-03-09 |
EP2293073B1 (en) | 2014-12-31 |
EP2287617A3 (en) | 2011-05-18 |
EP2293074A2 (en) | 2011-03-09 |
EP2287618A2 (en) | 2011-02-23 |
EP2287618B1 (en) | 2014-12-31 |
US20080318229A1 (en) | 2008-12-25 |
EP2293073A3 (en) | 2011-09-14 |
EP2339348B1 (en) | 2015-01-21 |
US20160161508A1 (en) | 2016-06-09 |
EP2287618A3 (en) | 2011-05-25 |
EP2293075A3 (en) | 2011-05-04 |
WO2006134390A2 (en) | 2006-12-21 |
EP2339348A2 (en) | 2011-06-29 |
GB0512401D0 (en) | 2005-07-27 |
EP2293074A3 (en) | 2011-05-04 |
EP3031823A1 (en) | 2016-06-15 |
EP3031823B1 (en) | 2018-12-19 |
WO2006134390A3 (en) | 2007-04-19 |
EP2287617B1 (en) | 2015-08-12 |
EP2293073A2 (en) | 2011-03-09 |
EP2287617A2 (en) | 2011-02-23 |
EP1891445A2 (en) | 2008-02-27 |
ES2533086T3 (es) | 2015-04-07 |
EP2339348A3 (en) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2534582T3 (es) | Procedimiento para diagnosticar una enfermedad neurodegenerativa | |
ATE456055T1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
AR054479A1 (es) | Metodo para diagnosticar l a enfermedad de alzheimer | |
Montecucco et al. | Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4 | |
Melero-Jerez et al. | The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis | |
WO2009132058A3 (en) | Levels of bcma protein expression on b cells and use in diagnostic methods | |
BR0108802A (pt) | Métodos de diagnóstico e terapêuticos para glaucoma | |
ES2570627T3 (es) | Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal | |
BR112018010266A2 (pt) | lactoferrina para uso no diagnóstico ou prognóstico da doença de alzheimer ou no diagnóstico da doença de parkinson | |
WO2020049438A3 (en) | System for detection of volatile organic compounds (voc) in exhaled breath for health monitoring | |
DE602004024539D1 (de) | Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben | |
Suarez‐Cedeno et al. | DNAJB6 myopathy: a vacuolar myopathy with childhood onset | |
MX2021007951A (es) | Ensayo multiplexado y metodos de uso del mismo. | |
ATE406579T1 (de) | Verfahren zur diagnose von tumoren | |
Schreiber et al. | A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity | |
Liang et al. | The effects of OB-induced depression on nociceptive behaviors induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus | |
Chen et al. | The first Chinese case of Creutzfeldt-Jakob disease with mutation of E200K in PRNP | |
CN110890133B (zh) | 急性反应期蛋白saa1在构建电离辐射后致死性预测模型或制备试剂盒、试剂的应用方法 | |
BR0015055A (pt) | Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr | |
IN2014MN01759A (es) | ||
BRPI0417291A (pt) | pano industrial, método para a formação de uma pano industrial e estrutura de pano industrial intermediário | |
Tarasova et al. | Intestinal microbiota composition in patients with multiple sclerosis | |
WO2006032021A3 (en) | Identification of gene associated with reading disability and uses therefor | |
WO2007058992A3 (en) | Mutations and polymorphisms of hdac6 | |
Chunduri et al. | Oral cysticercosis |